BioPhausia reschedules bank loan

BioPhausia's bank credit has been extended, and the Company has rescheduled its
bank loan. The bank increased BioPhausia's credit facility by SEK 50 million in
response to the Company's new supply contracts with two leading pharmacy chains.

On Friday, BioPhausia announced that it had signed long-term supply contracts
with Apoteksgruppen and another large pharmacy chain for the delivery of
parallel-imported drugs. The parallel trade represents an important business
area for BioPhausia and the two agreements are expected to give the Company's
sales a considerable boost.

"It is encouraging to see the bank supporting the Company's growth and
expansion," says BioPhausia's CEO Claes Thulin. "Our increased credit facility
is attributable to the signing of agreements with two important customers and
the value of these agreements to the Company's future growth."



For more information, please contact:

Claes Thulin, CEO, tel +46 (0)8-4076430

Henrik Wetterdal, CFO, tel +46 (0)8-4076430





[HUG#1414873]